JP2001517206A - 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 - Google Patents

免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Info

Publication number
JP2001517206A
JP2001517206A JP50973298A JP50973298A JP2001517206A JP 2001517206 A JP2001517206 A JP 2001517206A JP 50973298 A JP50973298 A JP 50973298A JP 50973298 A JP50973298 A JP 50973298A JP 2001517206 A JP2001517206 A JP 2001517206A
Authority
JP
Japan
Prior art keywords
melanoma
cell line
cells
antigens
shared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP50973298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001517206A5 (https=
Inventor
エム． パードル、ドゥリュー
エム． ジャフィー、エリザベス
アドゥラー、アダム
エル． トパリアン、スザンヌ
エイ． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2001517206A publication Critical patent/JP2001517206A/ja
Publication of JP2001517206A5 publication Critical patent/JP2001517206A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP50973298A 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Withdrawn JP2001517206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
US60/024,098 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007284431A Division JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Publications (2)

Publication Number Publication Date
JP2001517206A true JP2001517206A (ja) 2001-10-02
JP2001517206A5 JP2001517206A5 (https=) 2005-04-07

Family

ID=21818860

Family Applications (5)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Country Status (8)

Country Link
US (1) US6187306B1 (https=)
EP (1) EP0929318B1 (https=)
JP (5) JP2001517206A (https=)
AT (1) ATE283069T1 (https=)
AU (1) AU3889997A (https=)
CA (1) CA2263503C (https=)
DE (1) DE69731756T2 (https=)
WO (1) WO1998006746A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629178B2 (ja) 2016-11-22 2025-02-13 アロプレックス バイオセラピューティクス 同種異系腫瘍細胞ワクチン

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
JP2002506980A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2001098464A2 (en) * 2000-06-22 2001-12-27 Aventis Pasteur Limited Continuous adherent melanocyte cell line
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
DK1549353T3 (da) * 2002-10-09 2010-07-12 Central Iowa Health System Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2011049246A1 (ja) * 2009-10-23 2011-04-28 東レ・ダウコーニング株式会社 新規オルガノポリシロキサン共重合体
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
AU706443B2 (en) * 1994-04-22 1999-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Melanoma antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629178B2 (ja) 2016-11-22 2025-02-13 アロプレックス バイオセラピューティクス 同種異系腫瘍細胞ワクチン
US12403186B2 (en) 2016-11-22 2025-09-02 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine

Also Published As

Publication number Publication date
JP2014012738A (ja) 2014-01-23
WO1998006746A3 (en) 1998-05-07
WO1998006746A2 (en) 1998-02-19
DE69731756D1 (de) 2004-12-30
JP2008044969A (ja) 2008-02-28
US6187306B1 (en) 2001-02-13
JP2012001548A (ja) 2012-01-05
CA2263503C (en) 2012-04-10
AU3889997A (en) 1998-03-06
JP2016106137A (ja) 2016-06-16
CA2263503A1 (en) 1998-02-19
DE69731756T2 (de) 2005-12-15
EP0929318B1 (en) 2004-11-24
ATE283069T1 (de) 2004-12-15
EP0929318A2 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
JP2001517206A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US6350445B1 (en) Method of treating cancer with a tumor cell line having modified cytokine expression
Reilly et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
Ashley et al. Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
US7264820B2 (en) Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
Maraskovsky et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
EP1012240B1 (en) Cancer immunotherapy with semi-allogeneic cells
BG106028A (bg) Имунотерапия на рак чрез експресия на скъсен туморен или тумор-асоцииран антиген
JP2006502964A (ja) 特定の器官または組織に対する全身性免疫応答の標的化のための方法および組成物
KR20010021706A (ko) Ｍｈｃ 클래스 ⅱ 리간드의 예방접종을 위한 항항원체로의이용과 ｌａｇ-3의 암 치료에의 이용
EP0869803B1 (en) Allogeneic paracrine cytokine tumor vaccines
Mahvi et al. DNA cancer vaccines: a gene gun approach
Turner et al. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model
WO2009117011A1 (en) Tumor cell vaccines
Yei et al. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine
Davidoff et al. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
AU776795B2 (en) Chorionic gonadotropin DNA vaccines and methods
JP2020524997A (ja) 免疫応答を増強するための物質および方法
AU2004237854B2 (en) Melanoma cell lines expressing shared melanoma antigens and methods of using same
US6087174A (en) Growth medium for primary pancreatic tumor cell culture
JP4223813B2 (ja) 免疫増強特性を有するムチンペプチド
AU2008201147A1 (en) Melanoma cell lines expressing shared melanoma antigens and methods of using same
Penichet et al. A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity
de Zoeten et al. Tumor immunity in mice immunized with fibroblasts transfected with tumor DNA
EP0805207A1 (en) Polycistronic expression plasmid for tumor rejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100108